Evidence map›Paper›PMID 32540218›Full record

ArticleEuropean urology oncology2021

Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy.

Adam B Weiner, Farzana A Faisal, Elai Davicioni, R Jeffrey Karnes, Donald J Vander Griend, Tamara L Lotan, Edward M Schaeffer

Open access · hybridAbstract read
In one paragraph

Article in European urology oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Prostate-Specific Membrane Antigen-Targeted Imaging and Its Correlation with HOXB13 Expression.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  13. Review
  14. Review
  15. Article
  16. Role ofFrontiers in genetics · 2021
    Article
  17. HOXB13 and TFF3 can contribute to the prognostic stratification of prostate adenocarcinoma.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Adam B WeinerDepartment of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Farzana A FaisalBrady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Elai DavicioniDecipher Biosciences, Vancouver, BC, Canada.
R Jeffrey KarnesDepartment of Urology, Mayo Clinic Rochester, Rochester, MN, USA.
Donald J Vander GriendDepartment of Pathology, The University of Illinois at Chicago, Chicago, IL, USA.
Tamara L LotanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Edward M SchaefferDepartment of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address: e-schaeffer@northwestern.edu.
Northwestern University · USDecipher Biosciences (Canada) · CAJohns Hopkins Medicine · USJohns Hopkins University · USMayo Clinic · USUniversity of Illinois Chicago · US

Funding

Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancerP50CA180995 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABDULKADIR, SARKI A., HUSSAIN, MAHA H · 2015 to 2025
$19.9M
Multidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African AncestryU01CA196390 · NCI · JOHNS HOPKINS UNIVERSITY · PI DE MARZO, ANGELO MICHAEL, PIENTA, KENNETH J. · 2015 to 2020
$5.8M
NCI NIH HHS P50 CA180995NCI NIH HHS U01 CA196390
6 · The paper itself

Abstract

backgroundHomeobox B13 (HOXB13) expression regulates normal prostate development and mutations are associated with prostate cancer (PCa) formation.

objectiveTo assess the role of HOXB13 mRNA expression in PCa progression following radical prostatectomy. DESIGN, SETTING, AND

participantsGenome-wide expression profiles were queried from two retrospective prostatectomy cohorts with follow-up data (Mayo Clinic, n=780; Johns Hopkins Medical Institute [JHMI], n=355), and a prospective genomic registry (n=5239). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable Cox regressions were used to analyze metastasis-free survival (MFS). RESULTS AND LIMITATIONS: HOXB13 expression in primary PCa increased with increasing tumor grade and with high metastatic potential based on a genomic signature. The highest quartile of HOXB13 expression was associated with worse MFS compared with the lowest quartile (Mayo Clinic: adjusted hazard ratio [AHR] 1.46, 95% confidence interval [CI] 1.03-2.06, and JHMI: AHR 1.80, 95% CI 1.02-3.19). The combinations of high HOXB13 expression and low expression of its binding partner, MEIS1 (AHR 2.03, 95% CI 1.54-2.66) or MEIS2 (AHR 1.73, 95% CI 1.33-2.26), portended worse MFS. Additionally, high HOXB13 expression in combination with low MEIS1/2 expression correlated with high expression of androgen receptor-mediated genes. The retrospective nature of this study subjects the findings to a bias due to unmeasured variables.

conclusionsPrimary PCa tumors with increased HOXB13 expression have an increased propensity for metastases following prostatectomy, particularly in the setting of low MEIS1/2 expression. High androgen receptor output may account for worse outcomes for these tumors and suggests heightened sensitivity to androgen suppression. PATIENT SUMMARY: Using genomic data from a large number of prostate cancer (PCa) tumors, we found that increased expression of homeobox B13 (HOXB13), a gene related to normal prostate development, was associated with worse outcomes following surgery for PCa. A biomarker signature suggests that these tumors would be more susceptible to androgen suppression, a common treatment for PCa. Take Home  Messagece:: In multiple large cohorts, prostate cancer tumors with high homeobox B13 (HOXB13) expression and low expression of its binding partner MEIS1/2 were enriched with high androgen receptor output and had an increased propensity for metastases following surgery.

Indexed as

Genes, HomeoboxProstatic NeoplasmsHomeodomain ProteinsHumansMaleProspective StudiesProstateProstatectomyRetrospective StudiesHomeodomain ProteinsHOXB13 protein, humanDisease progressionHomeobox B13Homeodomain proteinsProstatic neoplasms

Identifiers

PMID32540218
PMCPMC7736205
OpenAlexW3035162230

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.